JP5479332B2 - 癌の診断方法および治療方法 - Google Patents

癌の診断方法および治療方法 Download PDF

Info

Publication number
JP5479332B2
JP5479332B2 JP2010512384A JP2010512384A JP5479332B2 JP 5479332 B2 JP5479332 B2 JP 5479332B2 JP 2010512384 A JP2010512384 A JP 2010512384A JP 2010512384 A JP2010512384 A JP 2010512384A JP 5479332 B2 JP5479332 B2 JP 5479332B2
Authority
JP
Japan
Prior art keywords
rrm1
expression
level
patients
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010512384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530746A5 (enExample
JP2010530746A (ja
Inventor
ジェロルド ベプラー，
Original Assignee
ユニヴァーシティ オブ サウス フロリダ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティ オブ サウス フロリダ filed Critical ユニヴァーシティ オブ サウス フロリダ
Publication of JP2010530746A publication Critical patent/JP2010530746A/ja
Publication of JP2010530746A5 publication Critical patent/JP2010530746A5/ja
Application granted granted Critical
Publication of JP5479332B2 publication Critical patent/JP5479332B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010512384A 2007-06-15 2008-06-13 癌の診断方法および治療方法 Expired - Fee Related JP5479332B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94415707P 2007-06-15 2007-06-15
US60/944,157 2007-06-15
US3955508P 2008-03-26 2008-03-26
US61/039,555 2008-03-26
PCT/US2008/066918 WO2008157353A1 (en) 2007-06-15 2008-06-13 Methods of diagnosing and treating cancer

Publications (3)

Publication Number Publication Date
JP2010530746A JP2010530746A (ja) 2010-09-16
JP2010530746A5 JP2010530746A5 (enExample) 2012-05-24
JP5479332B2 true JP5479332B2 (ja) 2014-04-23

Family

ID=40156627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512384A Expired - Fee Related JP5479332B2 (ja) 2007-06-15 2008-06-13 癌の診断方法および治療方法

Country Status (12)

Country Link
US (1) US20090017012A1 (enExample)
EP (1) EP2171086B1 (enExample)
JP (1) JP5479332B2 (enExample)
KR (1) KR20100044780A (enExample)
CN (1) CN101815793A (enExample)
AU (1) AU2008266048A1 (enExample)
BR (1) BRPI0813364A2 (enExample)
CA (1) CA2690865A1 (enExample)
ES (1) ES2401475T3 (enExample)
MX (1) MX2009013646A (enExample)
RU (1) RU2010101093A (enExample)
WO (1) WO2008157353A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9605657B2 (en) 2009-10-15 2017-03-28 Sumitomo Electric Industries, Ltd. Electric power generation system

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080026093A (ko) * 2005-05-04 2008-03-24 유니버시티 오브 사우스 플로리다 암 환자의 치료 반응을 예측하는 방법
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN107254538A (zh) 2008-11-12 2017-10-17 卡里斯生命科学瑞士控股有限责任公司 使用外来体来确定表现型的方法和系统
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
BR112012024590A2 (pt) 2010-03-29 2016-05-31 Abraxis Bioscience Inc métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
KR101602532B1 (ko) * 2013-08-29 2016-03-11 경북대학교 산학협력단 위암의 재발 가능성 예측을 위한 정보제공 방법
KR101949286B1 (ko) * 2015-10-26 2019-02-18 주식회사 싸이퍼롬 암 환자의 유전체 염기서열 변이 정보와 생존 정보를 이용한 맞춤형 약물 선택 방법 및 시스템
EP4178448A4 (en) * 2020-07-10 2025-06-18 Progenics Pharmaceuticals, Inc. Methods of making prostate cancer treatment decisions
CN113957145B (zh) * 2021-10-19 2023-09-26 中国医学科学院肿瘤医院 m6A相关lncRNA在预测小细胞肺癌预后和化疗反应的应用
CN114564622B (zh) * 2022-03-03 2025-07-25 苏州良医汇网络科技有限公司 一种tnm分期表录入系统的方法、装置以及设备

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705336A (en) * 1995-03-07 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Assay for sensitivity of tumors to DNA-platinating chemotherapy
US20020090642A1 (en) * 1995-12-11 2002-07-11 Patrick G. Johnston Methods for determining the prognosis of breast cancer using antibodies specific for thymidylate synthase
US6416987B1 (en) * 1997-02-04 2002-07-09 Sloan Kettering Institute For Cancer Research Mutants of thymidylate synthase and uses thereof
US6087489A (en) * 1998-06-02 2000-07-11 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of human thymidylate synthase expression
WO2001000799A1 (en) * 1999-06-28 2001-01-04 Takeda Chemical Industries, Ltd. Novel protein and dna thereof
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US7049059B2 (en) * 2000-12-01 2006-05-23 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
US6518416B1 (en) * 2000-12-01 2003-02-11 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6956111B2 (en) * 2001-03-02 2005-10-18 Response Genetics, Inc. Method of determining dihydropyrimidine dehydrogenase gene expression
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
EP1546376B9 (en) * 2002-09-30 2009-08-12 F.Hoffmann-La Roche Ag Oligonucleotides for genotyping thymidylate synthase gene
JP2007507770A (ja) * 2003-09-29 2007-03-29 パスワーク インフォーマティクス，インコーポレーテッド 生物学的特徴を検出するためのシステムおよび方法
KR20080026093A (ko) * 2005-05-04 2008-03-24 유니버시티 오브 사우스 플로리다 암 환자의 치료 반응을 예측하는 방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9605657B2 (en) 2009-10-15 2017-03-28 Sumitomo Electric Industries, Ltd. Electric power generation system

Also Published As

Publication number Publication date
RU2010101093A (ru) 2011-07-20
MX2009013646A (es) 2010-03-30
EP2171086B1 (en) 2012-12-19
ES2401475T3 (es) 2013-04-19
CA2690865A1 (en) 2008-12-24
US20090017012A1 (en) 2009-01-15
BRPI0813364A2 (pt) 2014-12-30
EP2171086A4 (en) 2010-10-13
WO2008157353A1 (en) 2008-12-24
JP2010530746A (ja) 2010-09-16
KR20100044780A (ko) 2010-04-30
AU2008266048A1 (en) 2008-12-24
EP2171086A1 (en) 2010-04-07
CN101815793A (zh) 2010-08-25

Similar Documents

Publication Publication Date Title
JP5479332B2 (ja) 癌の診断方法および治療方法
EP2527460B1 (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
CN109890982B (zh) 通过nrf2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法
JP6900314B2 (ja) 膀胱癌の治療、診断、及び予後判定方法
Ilson et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
US10456470B2 (en) Diagnostic methods and compositions for treatment of glioblastoma
US10208355B2 (en) Method of treatment for glioblastoma by administering a VEGF antagonist
JP2012196235A (ja) がんの対象における処置応答の予測
US20170166973A1 (en) Nucleic acid biomarker and use thereof
JP2011500046A (ja) Ｅｔ−７４３治療のための予後分子マーカー
JP7324769B2 (ja) 腫瘍細胞中のＲＡＤ５１ ｆｏｃｉの検出に基づく方法
CN102099493A (zh) 用于预测对抗癌疗法的反应性的组合方法
HK1144309A (en) Methods of diagnosing and treating cancer
Hager Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project
HK40012059B (en) Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130529

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130827

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140131

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140212

R150 Certificate of patent or registration of utility model

Ref document number: 5479332

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees